University of California San Francisco
Give to UCSFCombining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug.
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T
Cell biologist and engineer Matthew Kutys, PhD, and his team harness organoids – living tissues derived from patient tumors – to study how cancer spreads.
Eric J. Small, MD, UCSF professor of Medicine and Urology Credit: UCSFThe American Society of Clinical Oncology (ASCO) has elected Eric J. Small, MD, FASCO, to serve as its president for the term
Researchers at UCSF and UC Berkeley are investigating the impact of pre- and post-natal exposures to tobacco smoke on the survival rate of children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
A study on formula supplementation during breastfeeding aimed at improving infant growth found that once-daily formula supplementation is well-tolerated but doesn't improve growth.
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 65th Annual Meeting and Exposition. This year’s meeting will be held in San Diego from Dec. 8-12, 2023.
UCSF and UC San Diego scientists are beginning to uncover the long-term public health impacts of recurring environmental hazards such as flooding, wildfires or extreme heat.
Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
UCSF researchers found that regular screening is not always sufficient to prevent an advanced breast cancer diagnosis.
Breast cancer was the second most commonly diagnosed cancer in women, after skin cancer – accounting for 31% of all new female cancer diagnoses in 2022. Yet, determining who is most at risk of breast